Nanterre, 29 oct. 2026 (GLOBE NEWSWIRE) —Nanterre, le 29 octobre 2026 – North Atlantic France annonce, ce jour, sa décision d’augmenter à 75 € le prix par action de l’offre
Novos contratos com hotéis e a expansão da robótica contribuem para o progresso em direção à lucratividade do Grupo SINGAPURA e KUALA LUMPUR, Malásia, Oct. 28, 2026 (GLOBE NEWSWIRE) —
De nouveaux contrats hôteliers et l’extension des déploiements robotiques contribuent aux progrès vers la rentabilité du Groupe SINGAPOUR et KUALA LUMPUR, Malaisie, 29 oct. 2026 (GLOBE NEWSWIRE) — YYForce Inc.
New hotel contracts and robotics expansion support progress toward Group profitability SINGAPORE and KUALA LUMPUR, Malaysia, Oct. 28, 2026 (GLOBE NEWSWIRE) — YYForce Inc. (NASDAQ: YFOR) (“YYForce” or the “Company”),
Initial award funds process development, manufacturing, and clinical evaluation of a single-dose vaccine candidate through strategic partnerships with Hilleman Laboratories, SK bioscience, and IDT Biologika NEW YORK, NY, SINGAPORE, SG
Initial award funds process development, manufacturing, and clinical evaluation of a single-dose vaccine candidate through strategic partnerships with Hilleman Laboratories, SK bioscience, and IDT Biologika NEW YORK, NY, SINGAPORE, SG
Nanterre, 29 oct. 2026 (GLOBE NEWSWIRE) —Nanterre, le 29 octobre 2026 – North Atlantic France annonce, ce jour, sa décision d’augmenter à 75 € le prix par action de l’offre
Novos contratos com hotéis e a expansão da robótica contribuem para o progresso em direção à lucratividade do Grupo SINGAPURA e KUALA LUMPUR, Malásia, Oct. 28, 2026 (GLOBE NEWSWIRE) —
De nouveaux contrats hôteliers et l’extension des déploiements robotiques contribuent aux progrès vers la rentabilité du Groupe SINGAPOUR et KUALA LUMPUR, Malaisie, 29 oct. 2026 (GLOBE NEWSWIRE) — YYForce Inc.
New hotel contracts and robotics expansion support progress toward Group profitability SINGAPORE and KUALA LUMPUR, Malaysia, Oct. 28, 2026 (GLOBE NEWSWIRE) — YYForce Inc. (NASDAQ: YFOR) (“YYForce” or the “Company”),
Initial award funds process development, manufacturing, and clinical evaluation of a single-dose vaccine candidate through strategic partnerships with Hilleman Laboratories, SK bioscience, and IDT Biologika NEW YORK, NY, SINGAPORE, SG
Initial award funds process development, manufacturing, and clinical evaluation of a single-dose vaccine candidate through strategic partnerships with Hilleman Laboratories, SK bioscience, and IDT Biologika NEW YORK, NY, SINGAPORE, SG
